Pharma Two B Ltd.
๐ฎ๐ฑIsrael
- Country
- ๐ฎ๐ฑIsrael
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.pharma2b.com
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
Phase 3
Completed
- Conditions
- Parkinson DiseaseEarly Parkinson's Disease
- Interventions
- Drug: P2B001 0.6/0.75 mg
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Pharma Two B Ltd.
- Target Recruit Count
- 544
- Registration Number
- NCT03329508
- Locations
- ๐บ๐ธ
P2B001/003 site Boca Raton, Boca Raton, Florida, United States
๐บ๐ธP2B001/003 Study site little Rock, Little Rock, Arkansas, United States
๐บ๐ธP2B001/003 Site Scottsdale, Scottsdale, Arizona, United States
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),Drug: Placebo
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Pharma Two B Ltd.
- Target Recruit Count
- 149
- Registration Number
- NCT01968460
- Locations
- ๐บ๐ธ
P2B001 Site Los Angeles, Los Angeles, California, United States
๐บ๐ธP2B001 Manchester, Manchester, Connecticut, United States
๐ฎ๐ฑP2B001 Site Sourasky Medical Center, Tel Aviv, Israel
ยฉ Copyright 2025. All Rights Reserved by MedPath